{
  "@context": "https://frontierpicks.com/schemas/dossier.v1.json",
  "ticker": "AMLX",
  "name": "Amylyx Pharmaceuticals, Inc.",
  "url": "https://frontierpicks.com/dossiers/AMLX/",
  "json_url": "https://frontierpicks.com/dossiers/AMLX.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "Single-asset binary, now inside the guided window: Amylyx reaffirmed on 2026-08-06 that Phase 3 LUCIDITY topline for avexitide in post-bariatric hypoglycemia arrives late August or early September 2026. Sell-side marked targets up into it (BofA $30 on 2026-08-10, Baird $28 on 2026-08-07) while the stock cooled to $21.63 on 2026-08-14, 10.6% under its $24.19 high.",
  "invalidation_trigger": "A daily close below $18 (unwinds the bulk of the three-month advance built into the readout); secondarily, the company-guided late-August/early-September 2026 LUCIDITY topline window elapsing with neither data nor restated timing.",
  "catalyst_date": "2026-08-31",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Clinical-stage with no product revenue since RELYVRIO/ALBRIOZA's April 2024 US/Canada withdrawal; quarterly EPS lines carry no commercial signal.",
    "Topline can be released before the open on any business day inside the guided late-August/early-September 2026 window; the event is not calendar-fixed.",
    "Avexitide is a GLP-1 receptor antagonist, the opposite mechanism to semaglutide/tirzepatide; read-across from GLP-1 agonist headlines is unreliable.",
    "A 2026-08-06 wire headline carried cash of $279.8M; the company's own Q2 release states $250.8M in cash, equivalents and marketable securities at 2026-06-30."
  ],
  "body_markdown": "## Current Thesis\nThe event window is open. On 2026-08-06 Amylyx reaffirmed that topline data from the pivotal Phase 3 LUCIDITY trial of avexitide in post-bariatric hypoglycemia (PBH) is \"on track and anticipated in late August or early September 2026,\" with the last participant's final visit in the 16-week double-blind period already complete. Nothing else the company disclosed that day carries comparable weight: there is no product revenue, and the quarterly loss lines describe burn, not commercial traction.\n\nWhat changed since the last note is positioning, not information. The stock closed 2026-08-14 at $21.63, 10.6% below the $24.19 52-week high and 5.2% under the 2026-08-07 close of $22.82, with RSI(14) at 60.3 against 74.1 a week earlier. Over the same stretch two more firms raised targets — Baird to $28 from $19 on 2026-08-07, Bank of America to $30 from $22 on 2026-08-10 (TheFly headlines) — on top of Mizuho $24 (2026-07-20) and Citigroup $26 (2026-08-03). Published targets that sat on top of spot a week ago now sit above it, which removes one bear objection and replaces it with another: the number the print has to beat has moved up.\n\nThe narrative is **maturing**. The last piece of company-originated news is dated 2026-08-06; everything since is sell-side re-marking. Price is consolidating below the high while the momentum reading cools, and the newsflow calendar between 2026-08-08 and 2026-08-14 was empty. This is a known event with a well-populated bull file and moderating flow — the topline release itself will reset the label in a single session, in either direction.\n\n## Bull Case\n- **Phase 2b effect size was large on the same endpoint.** Avexitide 90 mg once daily produced a 64% least-squares mean reduction in the composite rate of Level 2 and Level 3 hypoglycemic events (ENDO 2025 exploratory analyses, 2025-07-13). LUCIDITY's FDA-agreed primary endpoint is that composite through Week 16.\n- **The trial is finished, not running.** Enrollment of 78 participants completed in March 2026; the 2026-08-06 release confirmed the last final study visit is done. The readout is a database-lock-and-unblind exercise, which is why the guided window is two weeks wide rather than a quarter.\n- **Targets moved up into the event.** Four raises in 22 days: Mizuho $24 (2026-07-20), Citigroup $26 (2026-08-03), Baird $28 from $19 (2026-08-07), BofA $30 from $22 (2026-08-10). Against the 2026-08-14 close of $21.63, the analyst-anchored gap is wider than it was on 2026-08-07.\n- **Launch scaffolding is already built.** The Expanded Access Program announced 2026-05-05 covers up to 250 US adults with PBH after Roux-en-Y gastric bypass, with initial participants drawn from LUCIDITY completers and prior avexitide studies — infrastructure that only matters if the drug reaches market.\n- **No financing gun to the head.** Cash, equivalents and marketable securities were $250.8M at 2026-06-30 with a company-stated runway into 2028 spanning topline, potential approval and a 2027 launch.\n- **Crowded short base.** Roughly 10.07M shares short, 12.64% of float, 6.1 days to cover (August 2026 settlement, short-interest trackers).\n\n## Bear Case\n- **78 patients, an event-rate endpoint.** PBH events are measured in CGM-monitored patients who also manage the condition behaviourally. Placebo-arm improvement compresses the delta that the Phase 2b 64% figure implies, and a trial this size has no room for a partial result.\n- **This management has taken a Phase 3 to the tape and lost.** PHOENIX missed on 2024-03-08; RELYVRIO/ALBRIOZA was voluntarily withdrawn from the US and Canadian markets on 2024-04-04, erasing the company's only commercial product.\n- **Raised targets are now an expectations problem.** A statistically positive result that lands materially short of the Phase 2b separation has to clear $28–$30 published targets set in the week before the readout.\n- **Burn against zero revenue.** Q2 2026 net loss $43.4M, or $(0.39) per share versus $(0.36) consensus, on R&D $23.8M and SG&A $21.9M, with 111.2M weighted-average shares.\n- **A single pivotal invites regulatory friction.** Breakthrough Therapy Designation shortens dialogue, it does not guarantee the FDA accepts one 78-patient trial as the whole efficacy package.\n- **Cash figure discrepancy in the wires.** A 2026-08-06 wire headline carried $279.8M; the company release states $250.8M at 2026-06-30. Readers pricing runway off the headline are working from the wrong number.\n\n## Setup & Price Structure\nReference close 2026-08-14: $21.63. Three-month return +62.8%; 52-week high $24.19 set earlier in August; distance from that high -10.6%. RSI(14) 60.3, down from 74.1 at the 2026-08-07 close of $22.82 — the advance has stopped extending while the guided window opened. Crowding observables, stated without a verdict: short interest at 12.64% of float and 6.1 days to cover; four price-target raises clustered into 2026-07-20 through 2026-08-10; no offering, S-3 takedown or insider transaction disclosed in the company newsroom between 2026-08-06 and 2026-08-14. The structure that matters is the summer base underneath — a decisive loss of the high-teens shelf would mean the market had begun discounting the readout rather than anticipating it.\n\n## Catalyst Calendar (next 30 days)\n\n- **~2026-08-31 (est.)** — Phase 3 LUCIDITY topline: avexitide 90 mg vs placebo, composite of Level 2 and Level 3 hypoglycemic events through Week 16, n=78. Releasable pre-market on any business day inside the guided window.\n- **~2026-09-07 (est.)** — Outer edge of the company-guided \"late August or early September 2026\" window. Passing it without data or restated timing pushes the next credible update to the Q3 2026 call.\n\n## Elapsed catalysts\n\n- **Post-topline, undated** — NDA submission timing and any financing decision. The company has said it is advancing NDA readiness toward a potential 2027 launch (2026-08-06); neither a filing date nor a capital plan has been given. *(passed 20d ago)*\n\n## What Would Change Our Mind\nThe structural break is the summer base giving way before the data, which would say the market is marking the trial down in advance: a daily close below $18 unwinds the bulk of the three-month advance and ends the pre-readout leg. Second, the guided window elapsing — no topline by roughly 2026-09-07 and no restated timing — turns a two-week binary into an open-ended wait and removes the reason the name re-rated in July and August. Third, on the data itself: a composite Level 2/3 reduction materially below the 64% least-squares mean seen for 90 mg QD in Phase 2b, or significance only on secondaries, would leave the equity anchored to cash of $250.8M (2026-06-30) plus a Phase 1/2 pipeline. An underwritten offering or disclosed ATM usage in the days after a positive print is the fourth item — it converts a clinical win into a share-count question before any revenue exists.\n\n## Correlation Notes\n- Event-day price action is idiosyncratic; small-cap biotech beta (XBI-type risk appetite) explains the drift into the print far better than the print itself. Inferred, not measured.\n- Read-across from GLP-1 agonist headlines (semaglutide, tirzepatide) is unreliable in both directions: avexitide is a GLP-1 receptor antagonist, the opposite mechanism.\n- The longer-dated market-size link runs the other way — sustained GLP-1 agonist adoption that reduces bariatric surgery volumes shrinks the incident PBH population that avexitide would be launched into.\n- Residual pipeline correlation is with rare-disease sentiment: AMX0035 in Wolfram syndrome and AMX0114 in ALS are Phase 2/Phase 1 assets carrying no near-dated catalyst inside this window.",
  "first_seen": "2026-08-07",
  "last_analyzed": "2026-08-19T11:46:01+00:00",
  "last_synthesized": "2026-08-16",
  "last_update_source": "theme_discovery",
  "license": "Content © FrontierPicks. Cite the canonical URL."
}